The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients receiving URD-HCT between 2000 and 2007 and reported to the European Group for Blood and Marrow Transplantation, was compared with that of 301 subjects, allografted from sib-HCT. With a median follow-up of 45 months, 3-year PFS approached 35% for both groups; overall survival (OS) was 42% for sib-HCT versus 37% for URD (NS). Multivariate analyses confirmed that donor type was not associated with differences in non-relapse mortality (NRM), relapse rate (RR), PFS or OS. Poor performance status (PS) and refractory disease adversely affected PFS and OS. Prior auto-SCT and multiple previous therapies predicted for shorter PFS. NRM was adversely affected by older age (X50 years), poor PS and refractory disease, and RR by time from diagnosis to allo-HCT of o36 months, prior auto-SCT, refractory disease, poor PS and in vivo T-cell depletion with alemtuzumab. This large study shows for the first time that URD-HCT is not inferior to sib-HCT, providing a reasonable therapeutic approach for DLBCL patients, having no HLA-identical sibling available.
INTRODUCTION
Although significant advances in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) have been made over the last few years, a large number of patients are not cured with conventional therapy. In relapsed disease, auto-SCT is the treatment of choice, resulting in long-term disease control in 40-50% of patients with chemosensitive disease compared with 10-20% patients with refractory disease. [1] [2] [3] [4] [5] The role of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of relapsed DLBCL remains undetermined, based on small series of patients. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Despite the potential for cure, allo-HCT is associated with toxicities that limit its widespread utilization; thus, the timing of transplantation and the optimal patient population still remain to be defined. Historically, allo-HCT was used in patients deemed not to be candidates for auto-SCT, due to disease extent, chemotherapy resistance, BM involvement or for those failing a previous autograft. Allo-HCT is often associated with lower disease relapse compared with auto-SCT, but nonrelapse mortality (NRM) and long-term morbidity offset this benefit. 11, 14, 15 Advances in supportive care, use of reduced-intensity conditioning (RIC) regimens and better unrelated donor (URD) selection have resulted in increasing use of allo-HCT in DLBCL. The strategy of reducing conditioning intensity is based on exploiting a GVL effect, whilst reducing upfront regimen-related toxicity. This approach is not yet shown to be superior to myeloablative regimens; 3 however, it allows patients who are otherwise ineligible for allo-HCT to undergo this procedure.
Further expansion in the number of candidates for allo-HCT is limited by availability of HLA-matched donors. URD allo-HCT (URD-HCT), despite being associated with a tendency for higher NRM compared with sib-HCT, was shown to provide long-term disease control in indolent lymphomas. 17 However, data on URD-HCT in DLBCL are extremely limited and include retrospective and prospective series reporting results of 10-60 subjects each, 3, [6] [7] [8] 10, 12, 13, 16, 18 precluding reliable conclusions in terms of safety and efficacy of URD-HCT compared with sib-HCT for this indication. 3, 6, 8, 9, 13, 14, 16, 18, 19 The objective of this retrospective analysis was to compare the outcomes of patients with DLBCL who received either a matched sibling (sib) or an URD-HCT in a large group of 473 patients.
PATIENTS AND METHODS

Data source
The European Group for Blood and Marrow Transplantation (EBMT) is a voluntary organization comprising 640 transplant centers mainly from Europe. Accreditation as a member center requires submission of minimal essential data (MED-A form) from all consecutive patients to the central registry where patients may be identified by the diagnosis of underlying disease and type of transplantation. Informed consent was obtained locally according to regulations applicable at the time of transplantation. Since 1996, accredited EBMT centers have been subject to on-site audits to assess data accuracy and consecutive reporting, and since January 2003, all transplant centers have been required to obtain written informed consent before data registration following the Helsinki Declaration 1975.
Patient eligibility
Patients older than 18 years with DLBCL who received an HLA-sib or URD-HCT from January 2000 to December 2007 and were reported to the EBMT were included in the analysis. Patients undergoing allo-SCT for transformed lymphoma, those receiving umbilical cord blood transplant and individuals who had a prior allo-HCT, were excluded from the study.
Outcomes and definitions
Histology was based on local reports. Conditioning regimens were defined as myeloablative or reduced intensity according to EBMT definitions. 20, 21 Any regimen with 50% or less equivalence to a standard conditioning regimen is considered non-myeloablative. This includes not only the 50% reduction of the total dose of a given drug (or total body irradiation (TBI)), but also the use of a single drug in a standard dose, without other drugs (or TBI) usually included in the standard protocol. The addition of antithymocyte globulin or any mono-or polyclonal anti-lymphocyte Ab or incorporation of purine analogues does not change the intensity category.
Computer tomography scans were employed to define response or disease progression following therapy. CR was defined as disappearance of tumor masses and disease-related symptoms. PR was considered when measurable lesions decreased by at least 50%. Relapse was defined as occurrence of new disease sites after a CR lasting for X3 months and progression when the CR lasted p3 months or had not been achieved. Relapse or progression was considered to be chemosensitive if at least PR was achieved following the last course of chemotherapy; otherwise, it was considered chemoresistant. 22 Grades II-IV acute GVHD (aGVHD) were defined according to the standard criteria. 23 Chronic GVHD (cGVHD) was evaluated in patients who engrafted and survived X100 days, and did not present disease progression. Thus, patients in whom cGVHD might be caused by cessation of immunosuppressive drugs or donor-lymphocyte infusion due to disease progression were excluded from the analyses for cGVHD, and only spontaneous cGVHD is presented herein. Poor performance status (PS) was defined as ECOG (Eastern Cooperative Oncology Group scale) X2 or Karnofsky score o80.
Policies at most European centers required high-resolution testing at HLA-A, -B, -C and -DRB1, with or without -DBQ1 level (8/8 or10/10), for URD matching. However, the EBMT definition for URD has changed over time, and currently requires 9/10-10/10 matched alleles. 24 Overall survival (OS) was defined as the time from transplant to death from any cause, with surviving patients censored at the last follow-up, and PFS as the time from transplant to recurrence, disease progression or death, with surviving patients without disease progression censored at the last follow-up. Both recurrence and progression were defined as disease progression with non-relapse deaths considered a competing event and NRM as death due to any cause, which occurred without previous disease progression after transplant.
Statistical analysis
The objective of the study was to compare the outcome of patients with DLBCL undergoing an URD-HCT in relation to those undergoing a sib-HCT, by adjusting for the potential differences existing between both groups. All the analyses were performed in the entire patient cohort considering donor type (URD-HCT versus sib-HCT) as the main study variable. Primary endpoints of the study were PFS and OS. Secondary endpoints were engraftment, GVHD, relapse/progression and NRM after HCT.
Patient and transplant characteristics were compared between the two groups using the w 2 -test or Fisher's exact test for categorical variables and the t-test or Mann-Whitney U-test for continuous variables. Probabilities of PFS and OS were calculated from the time of transplantation using the Kaplan-Meier product-limit estimate and compared by the two-tailed logrank test. Engraftment incidence of GVHD, NRM and relapse or progression after allo-SCT were calculated using cumulative incidences to account for competing risks.
Outcomes after transplantation for URD and sib donor groups were compared using Cox proportional hazards models, to adjust for patient-, disease and transplant-related variables. In addition to the type of donor, the main factor under study, the following covariates were considered: disease characteristics at diagnosis (stage, B symptoms, lactate dehydrogenase levels and presence of bulky disease), time interval between diagnosis and SCT, number of prior lines of therapy, prior auto-SCT, age at allo-SCT, PS and disease status at allo-HCT, type of conditioning regimen, year of allo-HCT, stem cell source, ex vivo T-cell depletion, in vivo T-cell depletion, anti-thymocyte globulin or anti-lymphocyte globulin administration, GVHD prophylaxis, donor/recipient sex match, ABO compatibility and donor/recipient CMV status. The assumption of proportional hazards for each factor in the Cox model was tested using time-dependent covariates. All variables satisfied the proportional assumption. All variables were tested for a significant interaction with the main factor under study. For the variables with a percentage of missing data 410%, a separate category named 'missing' was created to avoid loss of information in the multivariate analyses.
The impact of aGVHD and cGVHD on patient outcome was investigated by introducing GVHD as time-dependent covariates, taking into account that these are post-transplant events.
All P-values were two-sided. Cumulative incidences were calculated using the NCSS97 software (Number Cruncher Statistical System, Kaysville, UT, USA). All other computations were performed using the SPSS15.0 statistical package (SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
Characteristics of the entire cohort. Patient characteristics for 172 and 301 recipients of URD-HCT and sib-HCT, both at diagnosis and at the time of transplantation, as well as characteristics of the procedure itself, are shown in Table 1 .
In summary, the URD-HCT group represented a more heavily pre-treated patient population at the time of transplant, with longstanding disease compared with sib-HCT. Ninety-four percent of patients in the URD-HCT cohort received at least three prior therapeutic regimens compared with 65% of patients in the sib-HCT group (Po0.001), and two-thirds of URD-HCT recipients failed a prior auto-SCT compared with 52% of sib-HCT (P ¼ 0.003).
In contrast, a higher proportion of patients in the sib-HCT group were allografted in a poor PS (13% versus 7%, P ¼ 0.06).
In addition, the URD-HCT cohort more frequently failed rituximab-containing therapies (61.5% versus 49%, P ¼ 0.04) and was more commonly treated with serotherapy as part of the conditioning regimen (46% versus 15%, Po0.001).
Characteristics of patients undergoing allo-HCT without prior auto-SCT. Two hundred and three patients, 145 in the sib cohort and 58 in the URD group, underwent allo-HCT as their first high-dose therapy.
Median time from diagnosis to allograft was 16.5 months, ranging from 2.6 to 189 months, with no significant difference between patients undergoing sib versus URD-SCT. The median age of this entire cohort was 45 years, 40.8 years for patients undergoing URD-SCT versus 45 years for those transplanted from a sibling (P ¼ 0.03). The proportion of patients younger than 41 years was significantly higher in the URD versus the sib group, approaching 59% and 32%, respectively (P ¼ 0.02).
There were no differences in terms of disease stage at presentation, time from diagnosis to allograft, prior therapy with rituximab, disease status at transplantation, PS and the intensity of conditioning regimen between patients receiving a sib versus an URD allograft. In all 90.9% of those undergoing URD-SCT received at least three prior therapeutic regimens versus 49.4% of those undergoing a sib transplant (Po0.001).
Sixty patients (30%), 14 (24%) treated with URD and 46 (31.7%) with a sib transplant (P ¼ NS), were transplanted in first CR/PR, after receiving at least two prior therapies before achieving any response (n ¼ 54). Information regarding prior therapies was missing for six individuals. Notably, there were 11 patients who had their allograft at first chemosensitive relapse, after receiving at least three therapeutic regimens.
Engraftment. Fifteen patients died by day þ 14 post-transplant, and hence were non-evaluable for engraftment. Engraftment was achieved in 452 of the remaining 458 patients (99%). Six subjects reported as failing to engraft (four in URD-HCT cohort and two in sib-HCT) were NRM events within 50 days of stem cell infusion.
There were no significant differences in the cumulative incidence of granulocyte engraftment between URD-HCT and sib-HCT, with a cumulative incidence (CI) of engraftment at day 28 after HCT of 93% (95% CI, 90-97) and 93% (95% CI, 91-96), respectively ( Table 2) .
Median time for neutrophil 40.5 Â 10 9 /L and for platelet 450 Â 10 9 /L was 15 (7-44) and 13 (6-66) days, respectively. Granulocyte and platelet recoveries were significantly faster in patients allografted from PBSC than in those allografted from BM stem cells (14 versus 20 days, Po0.001, and 13 versus 29 days, Po0.001, respectively).
Relapse/progression and NRM. Relapse or progression after allo-HCT occurred in 172 patients. Median time to disease progression was 4 months (1-93) after transplantation. The cumulative incidence of disease progression after allo-HCT was 35% (95% CI, 31-40%) at 3 years for the whole group of patients, with no statistically significant difference between URD-HCT and sib-HCT (33% (95% CI, 27-41%) versus 36% (95% CI, 31-42%), P ¼ 0.1) (Figure 1a ) ( Table 2 ). Univariate analysis identified X3 prior lines of therapy (P ¼ 0.04), time from diagnosis o36 months (P ¼ 0.02), poor PS at allo-HCT (Po0.001), refractory disease (P ¼ 0.001) and 41% of patients undergoing Allo-SCT as their first high-dose therapy had RIC versus 64% of those having allograft as their second high-dose treatment (accounting for 72% of sib-HCT and 53% of URD-HCT).
Matched unrelated SCT in patients with DLBCL I Avivi et al in vivo T-cell depletion with alemtuzumab (P ¼ 0.02) as adverse prognostic factors for disease relapse/progression. The 3-year progression/relapse rate in patients transplanted with refractory disease approached 45.5% versus 35.5% in subjects transplanted with chemosensitive disease (P ¼ 0.001).
Of note, RIC protocols were also associated with a borderline higher relapse rate (RR) after allo-HCT (40% versus 33% at 3 years after transplantation, P ¼ 0.06; Figure 1b) , whereas rituximab administration as part of the salvage regimen applied at relapse had no statistically significant impact on RR.
All the above-mentioned variables identified by univariate analysis, together with autograft failure, were independent prognostic factors for RR in multivariate analysis (Table 3) . Risk of relapse or progression at 3 years for patients undergoing allograft after autograft approached 39.2%, compared with 34.6% in those having allo-HST as their first high-dose therapy (P ¼ NS).
One hundred and forty seven patients died without evidence of disease progression. The cumulative incidence of NRM was 16% (95% CI, 13-20%) at 100 days, 26% (95% CI, 22-30%) at 1 year and 30% (95% CI, 26-35%) at 3 years, with no significant differences between URD-HCT and sib-HCT (31% (95% CI, 25-39%) versus 29% (95% CI, 25-35%) at 3 years, respectively) ( Figure 1c) (Table 2 ). Older age (X50 years) (P ¼ 0.02), poor PS (P ¼ 0.02) and refractory disease (P ¼ 0.003) were associated with a higher NRM by both univariate and multivariate analysis ( Table 3 ). The 3-year NRM rate in patients transplanted with refractory disease was significantly higher than reported in patients transplanted with a chemosensitive disease (40.7% versus 28.8%, P ¼ 0.003).
Notably, RIC was not associated with a significantly reduced NRM rate as compared with CC regimen (the 3-year NRM approached 30.3% and 32.4%, respectively).
Reported causes of NRM for the entire cohort were: infections n ¼ 58, GVHD with or without concomitant infections n ¼ 45, pneumonitis n ¼ 3, adult respiratory distress syndrome n ¼ 2, multi-organ failure n ¼ 9, hemorrhage n ¼ 3, cardiac toxicity n ¼ 4, and the cause was not available for 23 patients.
PFS and OS. Three-year probabilities of PFS were 35% (95% CI, 28-43%) and 35% (95% CI, 29-40%), for URD-HCT and sib-HCT, respectively (P ¼ NS) (Figure 1d) (Table 2) . Three or more previous Abbreviations: aGVHD ¼ acute GVHD; Sib-HCT ¼ HLA-identical sibling donor hematopoietic cell transplantation; URD-HCT ¼ HLA-matched unrelated donor hematopoietic cell transplantation; CI ¼ cumulative incidence; NRM ¼ non-relapse mortality; OS ¼ overall survival.
Matched unrelated SCT in patients with DLBCL I Avivi et al treatment lines before allo-HCT, a previous failed auto-SCT, poor PS and refractory disease at allo-HCT were identified as independent adverse prognostic factors in the multivariate analysis ( Table 3 ). The 3-year PFS was significantly lower in patients transplanted with refractory compared with chemosensitive disease (13.8% versus 35.7%, Po0.001), and was marginally reduced in subjects transplanted after failing auto-SCT: 29.5% compared with 34.5% for patients undergoing allograft as their first high-dose therapy (P ¼ 0.2). Notably, the type of donor was not associated with different probabilities of PFS after allo-HCT, after adjusting for all relevant covariates. 
Matched unrelated SCT in patients with DLBCL I Avivi et al
At a median follow-up of 45 months for the 197 survivors, 3-year probabilities of OS were 37% (95% CI, 29-44%) and 42% (95% CI, 36-48%) (P ¼ NS), for URD-HCT and sib-HCT, respectively (Figure 1e ) ( Table 2) . Refractory disease and poor PS at allo-HCT were identified as adverse prognostic factors for OS in both univariate and multivariate analyses (Table 3 ). The 3-year OS in patients transplanted with refractory disease approached 24% versus 43.8% in those undergoing allograft with chemosensitive disease.
Of note, exposure to rituximab, prior auto-SCT and RIC regimen had no statistically significant impact on the 3-year OS (40.4% versus 39.5% with versus without rituximab, P ¼ NS; 38.4% versus 42.4% post auto-SCT versus without auto-SCT, P ¼ NS; and 38.7% versus 41.4% for RIC versus CC, P ¼ NS).
GVHD. aGVHD incidence and severity were similar in both groups ( Table 2 ). Day-100 cumulative incidence of aGVHD was 50% (95% CI, 46-55%) for the whole series; 53% (95% CI, 46-61%) for the URD-HCT group; and 48% (95% CI, 43-54%) for the sib-HCT group (Table 2 ). There were no differences in grades II-IV aGVHD incidence between URD-HCT and sib-HCT (36% (95% CI, 29-44%) and 32% (95% CI, 27-38%)). Introduction of grades II-IV aGVHD as a time-dependent variable in the model confirmed this event to be associated with a higher NRM (hazard ratio (HR) ¼ 1.4, 95% CI, 1-2.1, P ¼ 0.04) and a lower RR (HR ¼ 1.5, 95% CI, 1-2.1, P ¼ 0.03), but with no significant impact on PFS and OS. Notably, NRM rate in patients who developed grade IV approached 72%, resulting in a significantly decreased OS (1 year OS ¼ 6%).
Three hundred and seventeen patients (106 URDs and 211 sibs), fulfilling the criteria mentioned above, were evaluable for developing cGVHD. There were no significant differences between URD-HCT and sib-HCT in terms of cGVHD incidence, including extensive cGVHD, at 2 years after allo-HCT (36% (95% CI, 30-44%) versus 35% (95% CI, 27-46%)) ( Table 2 ). Introduction of cGVHD as a time-dependent variable showed it to be related to a higher NRM (HR ¼ 1.8 (95% CI, 1.1-3.1) P ¼ 0.03), and a tendency for a lower RR (HR ¼ 1.5 (95% CI, 0.9-2.5) P ¼ 0.1), but with no statistically significant impact on PFS and OS.
DISCUSSION
Several recent studies, almost all of them limited to small cohorts of participants, have suggested that with increased use of RIC regimens and better supportive measures, allo-HCT can become a treatment option for patients with relapsed/refractory DLBCL, particularly those who progress after auto-SCT. 3, 6, [8] [9] [10] 13 In addition, this treatment modality might also be considered in those patients experiencing early disease progression following rituximab-based induction therapy, whose 3-year PFS approaches 23% only, according to the CORAL Trial. 2 The widespread use of allo-HCT is at least partly hampered by the availability of an HLA-compatible donor.
The increased accessibility of a matched URD nowadays and the growing experience with URD-HCTs in different hematological malignancies have made this option more applicable to patients with DLBCL. The current study presents a very large registry analysis including about 500 DLBCL patients, comparing the outcome of subjects undergoing sib-HCT versus URD-HCT. Despite being retrospective in nature, and hence possessing inherent caveats, such as heterogeneity (differences in prior therapies, disease status at transplantation and conditioning regimen applied) and patient selection, it conveys two major conclusions. First, it confirms the encouraging results suggested by previously published series, which included smaller numbers of DLBCL subjects 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] 16, 18, 19, 25 (Table 4) , indicating the ability of allo-HCT to provide long-term disease control in 35% of the patients. Second, it demonstrates for the first time that URD-HCT provides an outcome similar to that obtained with sib-HCT in DLBCL subjects. These findings open an opportunity for curing many patients who would otherwise not be considered for allo-HCT, providing strong data that enable clinicians to refer patients to allograft, irrespective of the donor type available.
Notably, most previous studies exploring the allogeneic option in DLBCL patients predominantly analyzed sib-HCTs, with a limited number of matched unrelated allografts, without directly assessing the impact of donor type on transplant outcome. 3, [6] [7] [8] 10, 12, 13, 16, 18, 26, 27 As expected, the URD-HCT population of patients represented a poorer risk group in relation to the sib-HCT one, in whom the number of prior failed treatment lines, including a previous auto-SCT, was significantly lower. However, the proportion of patients transplanted with a poor PS was lower in the URD-HCT, and there were no differences in disease sensitivity at the time of transplant between the two cohorts.
Importantly, there was no statistically significant difference in time from CR to allo-HCT, indicating that patients undergoing URD-HCT did not represent a favorable group, in whom disease tended to progress slowly compared with those transplanted from a sibling donor. In spite of that, NRM did not significantly differ between the two treatment cohorts and was comparable to that reported in previous studies, 3, 16 comprising patients treated with RIC regimens only. 6, 10 As previously mentioned, allo-HCT was shown to provide a long-term disease control in 35% of the patients, irrespective of the donor type. Both PFS curves showed a plateau with time (with almost no increase in RR after 2 years post allograft), indicating that there seems to be a therapeutically beneficial GVL effect in this setting that can be exploited even in this subgroup of heavily pre-treated and refractory patients, as previously reported by other investigators. 6, 7, 10, 15, 19, 28, 29 As expected, PFS was dependent on the amount of therapy required before transplantation and by the chemosensitivity of the disease to the last therapeutic approach, administered before allo-HCT. The outcome of refractory patients is indeed disappointing; although still there are patients who are salvaged by this procedure, an observation that is in consensus with findings of the study by Hamadani et al. 30 reporting on a long-term PFS approaching 23% in these patients.
Disease recurrence represented the major cause of failure after allo-HCT, with most relapses seen during the first 2 years after the procedure. Notably, despite the greater employment of T-cell depletion strategies in subjects undergoing URD-HCT, the RR in these patients tended to be lower than observed in those receiving a sib-HCT, potentially indicating the existence of a more powerful graft-versus-malignancy effect in this setting, 31 although this difference did not reach a statistical significance. aGVHD and to a lesser extent cGHVD were indeed associated with a lower RR but this beneficial effect was somewhat obscured by a higher NRM, hence, did not translate into a significant improvement of PFS.
Notably, the intensity of the conditioning regimen had no statistically significant impact on the four outcomes analyzed. In a recent analysis of the EBMT Lymphoma Working Party, looking at the outcome of DLBCL patients undergoing allo-HSC after failing an auto-SCT, RIC protocols were associated with a lower NRM but a higher RR, hence, had no significant impact on PFS or OS. 3 The major advantage of RIC transplant would be opening a window of opportunity for patients who would otherwise not be eligible for an allogeneic HCT.
It should be emphasized that despite these relatively encouraging data, allo-HCT is not considered to be a common practice in heavily pre-treated patients in first CR or first chemosensitive relapse, whereas auto-SCT remains the treatment of choice. Nevertheless, the disappointing results of auto-SCT in patients with refractory/relapsed disease who received rituximab 2 raise the question whether these patients would do better if treated with allo-HCT rather than auto-SCT, as first high-dose therapy. Indeed, 203 patients in our series (accounting for 43%) had their allo-HCT without prior auto-SCT. Most of them failed at least two prior therapies, employed within less than 16 months before achieving any response. These clinical features, suggestive of an aggressive nature of the disease, appeared to convince their physicians to refer them to an allograft instead of auto-SCT. The comprehensive data provided in the current study, although unable to answer the question whether allo-HCT is superior to 'first salvage auto-SCT', demonstrate the achievement of long-term remissions in about one-third of these poor-risk patients. Moreover, auto-SCT would fail to control the disease in a substantial number of these patients, resulting in chemoresistance and subsequent relapses, which would prevent an opportunity of salvage allograft.
In summary, this study indicates that URD-HCT has comparable long-term outcomes to sib-HCT in relapsed DLBCL patients. If a patient is deemed to be a candidate for allo-HCT and does not have a sibling donor available, an URD search should be started to perform an URD-HCT in a timely fashion.
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